APOE and Alzheimer disease: Blood-based β-amyloid 42 and β-amyloid 40 ratio together with APOE genotype may be used as prescreening tests in primary care and in clinical Alzheimer disease trials to lower the costs and number of positron emission tomography scans and lumbar punctures.